UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in our charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of Principal Executive Offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
As of January 13, 2023, the Company had 18,367,757 shares of common stock outstanding. Since December 2021, the Company has issued 10,291,933 shares of common stock as a result of exercise of conversions of 6,965 shares of Series A Preferred Stock. As of January 13, 2023, there were 13,035 shares of Series A Preferred Stock issued and outstanding.
1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Allarity Therapeutics, Inc. | ||
By: | /s/ James G. Cullem | |
James G. Cullem Chief Executive Officer | ||
Dated: January 17, 2023 |
2
Cover |
Jan. 13, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 13, 2023 |
Entity File Number | 001-41160 |
Entity Registrant Name | ALLARITY THERAPEUTICS, INC. |
Entity Central Index Key | 0001860657 |
Entity Tax Identification Number | 87-2147982 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 24 School Street |
Entity Address, Address Line Two | 2nd Floor |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02108 |
City Area Code | 401 |
Local Phone Number | 426-4664 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | ALLR |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
FPW'YH!Q$'@-,0A\.B,#!H_R2BDP\HK85Y(^L;2+ ;;=[1;0A =9]%3=LP5#(@FK5T'.O#
MQ[XEO=$FM5:.=-OG1@$\JJO$#,7$6P(D2KJM6702SB6W,3 L(:2$NB4KU0:
MTUY853%5K$E,T@>L5S(A",D(-VB"9?A$[+]+2[%4DKN,.Y_0.B 61@Q&E+S9
MRO!SI*!K%G BVIH8(&')^?4Y8I&Q%7?L/L[&Q5VPE_^(1M&U0E0YBYK$ND!5
M/"!9-);'%ZA\
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M$\:!5\":IU\ !+_.4JK#=[29",J6PZ&V_RL@PN>82//3?B-_?8]G0]$=3U
M<6LZ4>>^5;BBGWZ[K6'SR6JJ'S^#O4D!8QE5&Q